Bluebird bio went from a high-flying $10 billion company during the heyday of gene therapy to being sold for a measly $29 ...

When some for­mer MyoKar­dia ex­ecs re­unit­ed with $300 mil­lion for a new “heart health” biotech ear­li­er this year, they ...

Johnson & Johnson ends Phase 3 trial of depression drug aticaprant due to poor efficacy, following similar setback for ...

Bayer is asking shareholders to authorize a potential equity offer that would allow it to quickly raise billions of euros to ...

New York-based Sycamore Partners is acquiring Walgreens for $11.45 a share in cash, the companies announced Thursday.

Roche announced a new research hub on Friday in partnership with Harvard that it hopes will accelerate efforts in disease ...

Novo Nordisk's rare disease unit awaits Phase 3 data for etavopivat in sickle cell disease, aiming for 50% VOC reduction ...

President Trump's nominees for NIH director and FDA commissioner sailed through their respective confirmation hearings, ...

More generic drug prices decreased than increased in January, while nearly 1,000 brand-name drugs saw their prices increase ...

John McHutchison started Monday as CEO and chairman of Tune Therapeutics, after sitting on the company’s board for two years.

Ahead of Merck KGaA’s earnings announcement Thursday, investors were mostly looking forward to any comments about its ...

Johns Hop­kins sur­geon Mar­ty Makary, Pres­i­dent Don­ald Trump’s pick to lead the FDA, emerged from his Sen­ate ...